Official global newsroom account for Biogen, a leading biotech company pioneering innovative science since 1978. Community guidelines: bit.ly/1MZocKs
Joined June 2010
- Tweets 5,990
- Following 241
- Followers 44,783
- Likes 1,234
1,994 Photos and videos
#News: Today, we announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for an investigational therapy for spinal muscular atrophy (SMA). Learn more about this important milestone: bit.ly/49B9vj0
3
14
1,120
#News: With @ucb_news, we announced data at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress, for an investigational therapy for systemic lupus erythematosus (SLE). Learn more about the data: bit.ly/4uTeELQ
1
7
518
#News: Today we announced we’re sharing 14 abstracts highlighting data from our nephrology portfolio at the European Renal Association (ERA) and American Transplant Congresses (ATC). Read more about our upcoming kidney presentations: bit.ly/4ug63Sm
2
7
596
We’re attending the @ERAkidney Congress to share data on our investigational therapy targeting CD-38 cells in immune-mediated diseases. Join us to learn about our ongoing research and late-stage pipeline: ow.ly/rEhj50Z6Oyr
6
466
We’re joining the global rheumatology community at @eular_org to share our latest research focused on systemic lupus erythematosus (SLE). Find us at #EULAR2026 and learn more about our work in lupus: ow.ly/2VH250Z6GX3
1
1
6
769
#News: With @ucb_news, we’re pleased to share that @TheLancet has published full results from a positive Phase 3 study for an investigational treatment for systemic lupus erythematosus (SLE). Read more: bit.ly/4a07FYY
2
7
473
#News: We announced topline results from a Phase 2 study for an investigational drug targeting tau in individuals with early Alzheimer’s disease. These results represent an important milestone for the field. Learn more: bit.ly/4uemzD8
2
10
1,305
#News: Today, we announced the successful completion of the acquisition of Apellis Pharmaceuticals. Learn more about this news: bit.ly/3Rbo1HE
4
618
STARTING SOON: Join our Q1 2026 financial results live webcast at 8AM ET. Join here: bit.ly/4w1kY4Y
#Earnings $BIIB
1
1
2
571
Today, we reported our Q1 results which reflect our meaningful progress advancing the New Biogen, focused on strong commercial and pipeline execution. Read more: bit.ly/4un5qH7
Forward-looking statements: biogen.com/forward-looking-s…
#Earnings $BIIB
1
1
2
649
Meet us at the #ChinaBioPartnering Forum April 28-29 and join our sessions to learn about Biogen’s focus on partnering for global impact and our commitment to innovation from China.
Discover our partnering opportunities across the globe: ow.ly/l9go50YP4pb
1
3
420
#News: We announced an agreement with TJ Biopharma to acquire exclusive rights to an investigational treatment for immune-mediated diseases in the Greater China Region. With this, we will now own exclusive worldwide rights to this CD-38 directed antibody. bit.ly/4dYt33E
2
3
950
#News: We announced that we have entered into a definitive agreement to acquire @ApellisPharma. This potential acquisition will bring two best-in-class commercialized immunology medicines to Biogen and accelerate our entry into nephrology. Read more: ow.ly/3PcZ50YB7Pp
1
3
5
951
#News: Today, the FDA approved a new dosing regimen option for our spinal muscular atrophy (SMA) therapy. This approval represents an important step toward expanding options for people living with SMA. Learn more: ow.ly/94tg50YAA9p
6
9
1,728
#News: At #AAD2026, we’re presenting new data for an investigational medicine for cutaneous lupus erythematosus (CLE), highlighting our ongoing efforts to advance a potential new option for people living with this serious form of lupus.
Read more: ow.ly/c1tA50YA3J7
4
7
1,034
#News: Together with Eisai, we’re sharing new real-world data at #ADPD2026 evaluating long-term treatment persistence in the U.S. among people living with early Alzheimer’s disease. Read more: ow.ly/xbA650YwTRL
1
4
690
#News: Join us at the American Academy of Dermatology (AAD) Annual Meeting to learn about our late-breaking research for a potential cutaneous lupus erythematosus (CLE) treatment. Read more about the data we’re sharing at #AAD2026: ow.ly/bxpm50YwfPz
1
3
782
We’re heading to #ADPD2026 to discuss the latest research, clinical trials, and treatments for Alzheimer's disease (AD) and Parkinson's disease. Find us at Booth #2 to learn how we’re advancing research in this space. Learn more: ow.ly/HwZT50YuT70
4
548
#News: At the 2026 #MDAConference, hosted by @MDAorg, we’re presenting new Phase 1b results and details on the Phase 3 clinical development program for an investigational spinal muscular atrophy (SMA) medicine. Read more: ow.ly/g07g50YshGO
1
2
3
802